Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A pill aimed at Hard-to-Treat cancers: scientists test YF087 in tumors with broken DNA repair

NCT ID NCT07809607

Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing an experimental daily pill called YF087 in adults with advanced solid tumors that have a genetic feature called MSI-H or dMMR. These tumors often stop responding to standard immunotherapy, so new options are needed. The phase 1 trial aims to find a safe dose, check for side effects, and see how the body processes the drug. About 70 participants will take YF087 once a day, and doctors will track tumor response and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental oral drug called YF087
What this could lead to
If YF087 proves safe and shows signs of shrinking these tumors, it could become a new oral option for cancers with MSI-H or dMMR features that have stopped responding to standard immunotherapy.
What could go wrong
This is a first-in-human phase 1 trial with about 70 participants, so its main goal is checking safety and finding a dose, not proving the drug works. Many experimental cancer drugs fail at this stage, and YF087 may cause side effects or show too little benefit to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with locally advanced (unresectable) or metastatic solid tumors; * dMMR/MSI-H status demonstrated in tumor tissue, blood, or other samples containing cancer cells or DNA; * Subjects must have experienced disease progression after the most recent therapy for advanced disease (prior therapy must include at least one PD-1/PD-L1 inhibitor treatment). * Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; * ECOG≤1 Exclusion Criteria: * Prior treatment with a WRN inhibitor such as HRO760, RO7589831, GSK4418959 and NDI-219216; * Prior to the first dose of study intervention, receipt of any anticancer treatment (including chemotherapy, targeted therapy, immunotherapy, etc.) or any other investigational medicinal product within 14 days or 3 half-lives (whichever is shorter); * Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases and/or leptomeningeal carcinomatosis and/or brainstem metastases and/or spinal cord compression; * Subjects with clinically significant cardiovascular and cerebrovascular disease * Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases; * Use of, or planned use of, any of the following medications that has not been discontinued for at least 14 days or 5 half-lives (whichever is shorter) before the first study drug administration: 1. Strong CYP3A4 inducers or inhibitors; 2. Drugs known to prolong the QT interval. * Pregnant or lactating females;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.